US 11,859,003 B2
Method for treating cancer using anti-CD137 antibody
Peter Peizhi Luo, Suzhou (CN); Fangyong Du, Suzhou (CN); Guizhong Liu, Suzhou (CN); Yan Li, Suzhou (CN); Jun Chen, Suzhou (CN); Xiaohong She, Suzhou (CN); and Peter Cheung, Suzhou (CN)
Assigned to Adagene Inc., Grand Cayman (KY)
Appl. No. 16/640,684
Filed by Adagene Inc., Grand Cayman (KY)
PCT Filed Aug. 21, 2018, PCT No. PCT/CN2018/101501
§ 371(c)(1), (2) Date Feb. 20, 2020,
PCT Pub. No. WO2019/037711, PCT Pub. Date Feb. 28, 2019.
Prior Publication US 2020/0369776 A1, Nov. 26, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/001102 (2018.08); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method for treating a cancer in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, that binds to an extracellular domain of human CD137, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region,
wherein:
(i) the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO:731, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:755, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:779; and
(ii) the light chain variable region comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO:803, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:827, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:851.